Akribion Therapeutics Secures €8M to Advance CRISPR-Based Cell Depletion Technology

CRISPR specialist Akribion ​​Therapeutics, a spin-off of BRAIN Biotech AG, is receiving fresh liquid funds of eight million euros as part of a seed financing round. This means that the company, which was only founded in 2024, has left stealth mode.

Led by CARMA FUND and RV Invest, MP Beteiligungs GmbH, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds also participated in the financing round. The liquid funds are intended to provide proof of concept in vivo, i.e. in a living organism, of the Akribion ​​technology. According to the company, this is a “unique, RNA-controlled, nuclease-based technology for programmable cell depletion”.

“Akribion’s approach opens up a whole new class of therapeutic possibilities. Our proprietary G-dase E nucleases enable very specific depletion of certain subsets of cells based on the presence of a specific RNA sequence,” said co-founder and Akribion ​​co-CEO Lukas Linnig. “Although we are initially focused on developing breakthrough precise oncology therapies, we believe that this programmable cell depletion approach could have a much broader application.”

Admittedly, Akribion’s developments are still at a very early stage

Nevertheless, the financing round is clearly to be viewed positively, also for BRAIN Biotech, from which the company emerged.

The Hessian company only finalized the spin-off in the fall of last year. “The spin-off of Akribion ​​Therapeutics has positive effects on our running costs. This should be reflected in the figures from the second quarter of 2024/25 ,” said BRAIN Biotech CFO Michael Schneiders in an interview at the Equity Forum 2024 in Frankfurt.

Based on the exclusive technology license agreement for the pharmaceutical sector, BRAIN Biotech is entitled to up to 92.3 million euros in R&D and commercial milestone payments. The highlight: the Hessian company retains the non-pharmaceutical-related rights to the proprietary CRISPR technology.

Akribion’s developments are still in their infancy. Nevertheless, this is a very interesting spin-off that could bring BRAIN Biotech a lot of joy in the long term. The small cap is a clear speculative buy at the current price level (stop: 2.75 euros). Important: Due to the low trading volume, orders should be limited.

__

(Featured image by digitale.de via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in DER AKTIONAR. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us